Read by QxMD icon Read

Hyperplasia prostatic benign

M J Young, M Elmussareh, T Morrison, J R Wilson
Introduction Transurethral resection of the prostate (TURP) is considered the gold standard surgical treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. The number of TURPs performed has declined significantly over the last three decades owing to pharmaceutical therapy. TURP data from a single institution for the years 1990, 2000 and 2010 were compared to assess the difference in performance. Methods A retrospective analysis was undertaken of all patients who underwent TURP between January and December 2010...
March 15, 2018: Annals of the Royal College of Surgeons of England
Steven A Kaplan
No abstract text is available yet for this article.
May 2017: Journal of Urology
Steven A Kaplan
No abstract text is available yet for this article.
May 2017: Journal of Urology
Shamar Young, Jafar Golzarian
PURPOSE OF REVIEW: Over the last several years prostate artery embolization (PAE) has been developed as a minimally invasive technique for the treatment of benign prostatic hyperplasia induced lower urinary tract symptoms. This review aims to elucidate the data available on this developing technique and identify areas requiring further investigation. RECENT FINDINGS: Recent studies have demonstrated that PAE is able to deliver excellent clinical outcomes in terms of International Prostate Symptom Score, quality-of-life score, maximum urinary flow rate, post-void residual, and prostate volume reduction...
March 13, 2018: Current Opinion in Urology
Tim Large, Amy E Krambeck
PURPOSE OF REVIEW: Holmium laser enucleation of the prostate (HoLEP) has been a mainstay therapy for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostate hyperplasia (BPH) for nearly 20 years. We briefly review current and sentinel publications that provide outcomes data after HoLEP. RECENT FINDINGS: Current literature continues to support HoLEP as a versatile and durable surgical option for men with LUTS secondary to BPH. Despite evidence supporting durable symptom relief beyond 10 years even in large prostate glands, HoLEP is still not widely available to all patients...
March 13, 2018: Current Opinion in Urology
Verena Lieb, Katrin Weigelt, Lena Scheinost, Kersten Fischer, Thomas Greither, Marios Marcou, Gerit Theil, Helmut Klocker, Hans-Juergen Holzhausen, Xin Lai, Julio Vera, Arif B Ekici, Wolfgang Horninger, Paolo Fornara, Bernd Wullich, Helge Taubert, Sven Wach
We studied the association of the serum levels of the microRNA family members miR-320a/-b/-c with clinico-pathological data to assess their applicability as diagnostic biomarker in prostate cancer (PCa) patients. The levels of miR-320a/-b/-c in 3 groups were evaluated by qRT-PCR (145 patients with PCa, 31 patients with benign prostatic hyperplasia (BPH) and 19 healthy controls). The levels of the three family members of miR-320 were directly correlated within each group ( P < 0.001), but they differed significantly among the three groups ( P < 0...
February 13, 2018: Oncotarget
Christian D Fankhauser, Peter J Schüffler, Silke Gillessen, Aurelius Omlin, Niels J Rupp, Jan H Rueschoff, Thomas Hermanns, Cedric Poyet, Tullio Sulser, Holger Moch, Peter J Wild
Background: We aimed to analyze the frequency and distribution of PD-L1 expression in specimens from prostate cancer (PC) patients using two different anti-PD-L1 antibodies (E1L3N, SP263). Materials and Methods: PD-L1 immunohistochemistry was performed in a tissue microarray consisting of 82 castration-resistant prostate cancer (CRPC) specimens, 70 benign prostate hyperplasia (BPH) specimens, 96 localized PC cases, and 3 PC cell lines, using two different antibodies (clones E1L3N, and SP263)...
February 13, 2018: Oncotarget
Donggen Jiang, Chutian Xiao, Tuzeng Xian, Liantao Wang, Yunhua Mao, Junfu Zhang, Jun Pang
Background: Doublecortin-like kinase 1 (DCLK1) has been proven to be involved in numerous tumors, while its role in prostate cancer (PCa) is still unclear. This study aimed at investigating the expression pattern and prognostic value of DCLK1 in PCa. Patients and methods: Real-time polymerase chain reaction and Western blot were employed to determine DCLK1 mRNA and protein levels in 25 paired fresh samples of PCa and benign prostatic hyperplasia (BPH) as well as in PCa cell lines...
2018: OncoTargets and Therapy
Chunwei Ye, Yi Cai, Qian Cai, Shunhui Yuan, Fan Huang, Xiaofang Yang, Shuchen He, Zhuoheng Li, Yanwen Wang, Delin Yang, Zhipeng Li
The aim of the present study was to investigate the candidate genes and pathways associated with benign prostatic hyperplasia (BPH) and diabetes. In vitro experiments were performed using normal prostatic epithelial RWPE‑1 and HPr‑1 cells. The cell lines were treated with a high‑glucose solution and MTS and bromodeoxyuridine assays were used to assess cell viability. Transcriptome sequencing was used to screen the candidate genes. The expression of candidate genes was further verified by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting...
March 7, 2018: International Journal of Molecular Medicine
Feng Li, Laura E Pascal, Jianhua Zhou, Yibin Zhou, Ke Wang, Anil V Parwani, Rajiv Dhir, Peng Guo, Dalin He, Joel B Nelson, Zhou Wang
The mechanisms involved in the development of benign prostatic hyperplasia (BPH) are poorly understood. One potential mechanism involved in BPH pathogenesis may involve altered expression of genes related to apoptosis and proliferation because reduced cell death and increased proliferation are thought to contribute to prostatic enlargement. This study examined the expression of B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra large (BCL-XL), two important anti-apoptosis factors that are also capable of inhibiting cell proliferation via accelerated G1 arrest or delayed G1/S transition, using immunostaining in simple prostatectomy BPH specimens from patients naïve to androgen manipulation...
2018: American Journal of Clinical and Experimental Urology
Piyush Pathak, Sevann Helo, Kevin T McVary
Management of benign prostatic hyperplasia focuses on relief of lower urinary tract symptoms (LUTSs), improvement of quality of life, and prevention of symptom progression. Minimally invasive surgical treatments (MISTs) offer potential for rapid symptomatic relief, medication independence, and less perioperative risk. The Rezūm system is a novel MIST that uses water vapor thermal therapy to ablate obstructive prostate tissue. In this review, we summarize the data revealing that water vapor thermal therapy provides clinically meaningful, rapid, and durable relief of LUTSs in both storage and voiding functions while providing a minimal impact on sexual function...
March 9, 2018: European Urology Focus
Joo Yong Lee, Kang Su Cho
PURPOSE OF REVIEW: The use of 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) and other diseases has been proposed and studied. However, the controversy about its benefits and harms for other diseases has persisted. In this review, we will discuss the newly identified effects of 5ARIs based on recently published studies. RECENT FINDINGS: These drugs are currently recommended in clinical guidelines for BPH. However, the reporting of adverse effects, including sexual dysfunction as well as neurologic, endocrine, and cardiovascular effects, have been controversial...
March 9, 2018: Current Opinion in Urology
Livio Mordasini, Marco Moschini, Agostino Mattei, Christophe Iselin
PURPOSE OF REVIEW: GreenLight photoselective vaporization (GL-PV) is now established in the treatment of benign prostatic enlargement. The present review outlines the available technical armamentarium and summarizes the current best evidence on functional and safety outcomes. Moreover, future technical developments and refinements are presented. RECENT FINDINGS: GL-PV has evolved to be the most commonly performed procedure, second to conventional transurethral resection of the prostate (TURP) for surgical management of benign prostatic obstruction (BPO)...
March 9, 2018: Current Opinion in Urology
Visalini Nair-Shalliker, Albert Bang, Marianne Weber, David E Goldsbury, Michael Caruana, Jon Emery, Emily Banks, Karen Canfell, Dianne L O'Connell, David P Smith
Australia has one of the highest incidence rates of prostate cancer (PC) worldwide, due in part to widespread prostate specific antigen (PSA) testing. We aimed to identify factors associated with PSA testing in Australian men without a diagnosis of prostate cancer or prior prostate disease. Participants were men joining the 45 and Up Study in 2006-2009, aged ≥45 years at recruitment. Self-completed questionnaires were linked to cancer registrations, hospitalisations, health services data and deaths. Men with a history of PC, radical prostatectomy or a "monitoring" PSA test for prostate disease were excluded...
March 9, 2018: Scientific Reports
Haidy E Zidan, Rehab S Abdul-Maksoud, Walid S H Elsayed, Esam A M Desoky
Prostate cancer (PCa) is considered the most common malignancy in men. The aim of this study is to assess the role of serum miR-15a and miR-16-1 expression in PCa development, diagnosis and prognosis aiming to find a specific noninvasive biomarker. This study comprised 70 patients with PCa, 70 patients complaining of benign prostatic hyperplasia (BPH), 30 patients with chronic prostatitis and 70 controls. Circulating miR-15a and miR-16-1 expression was detected by real-time polymerase chain reaction. Prostate specific antigen levels were measured by enzyme-linked immunosorbent assay...
March 9, 2018: IUBMB Life
Young Ju Lee, Seung-June Oh
PURPOSE: To report de novo calculi in the prostatic surgical bed as a complication of Holmium laser enucleation of the prostate (HoLEP). MATERIALS AND METHODS: Patients who underwent HoLEP and were enrolled in our Benign Prostatic Hyperplasia (BPH) Database Registry from July 2008 to December 2015 were reviewed. Cases of calculi removal in the prostatic surgical bed were identified. Clinical data, including preoperative evaluation, postoperative symptoms with a detailed history, urinalysis, pathology, cystourethroscopy, and stone analysis were collected and described...
March 7, 2018: Urology Journal
Guinevere Stevina Margaretha Kammeijer, Jan Nouta, Jean de la Rosette, Theo M de Reijke, Manfred Wuhrer
The concentration of prostate specific antigen (PSA) in serum is used as an early detection method of prostate cancer (PCa) showing, however, low sensitivity, specificity and a poor predictive value. Initial studies suggested the glycosylation of PSA to be a promising marker for a more specific yet non-invasive PCa diagnosis. Recent studies on the molecular features of PSA glycosylation (such as antenna modification and core fucosylation) were not successful in demonstrating its potential for an improved PCa diagnosis, probably due to the lack of analytical sensitivity and specificity of the applied assays...
March 4, 2018: Analytical Chemistry
Eunsook Park, Mee-Young Lee, Woo-Young Jeon, Chang-Seob Seo, Sooseong You, Hyeun-Kyoo Shin
ETHNOPHARMACOLOGICAL RELEVANCE: Paljung-san is a traditional herbal medicine used widely for the treatment of urogenital diseases in East Asia. However, scientific evidence of the efficacy of Paljung-san and its mechanisms of action against benign prostatic hyperplasia (BPH) is not clearly established. AIM OF THE STUDY: We investigated the inhibitory effect of Paljung-san water extract (PSWE) and its mechanisms against BPH in vitro and in vivo. MATERIALS AND METHODS: Active compounds of PSWE were analyzed quantitatively by High-performance liquid chromatography (HPLC)...
February 28, 2018: Journal of Ethnopharmacology
Nikhil Gupta, Tyson Rogers, Bradley Holland, Sevann Helo, Danuta Dynda, Kevin T McVary
PURPOSE: This evaluation of long-term outcomes of treatment for lower urinary tract symptoms due to benign prostatic hyperplasia compares a one-time water vapor thermal therapy procedure with daily medical therapy in cohorts from the Medical Therapy of Prostatic Symptoms (MTOPS) study. MATERIALS AND METHODS: Results from the treatment arm of a randomized, controlled trial of thermal therapy (Rezūm System) were compared to MTOPS subjects treated with doxazosin, finasteride, or both...
February 27, 2018: Journal of Urology
Fu-Yu Lin, Yi-Chien Yang, Cheng-Li Lin, Lukas Jyuhn-Hsiarn Lee
BACKGROUND: Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disorder characterized by typical motor impairment. However, lower urinary tract symptoms, including urinary urgency or frequency, which are non-motor phenomena, occur frequently among patients with IPD. In this study, we assess the risk of overactive bladder (OAB) in patients with IPD. METHODS: The National Health Insurance Research Database of Taiwan was used to identify patients with IPD (IPD cohort) and four-fold controls (non-IPD cohort) from 2000 to 2010...
2018: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"